- Home
- GRPN vs BCYC Comparison
GRPN vs BCYC Comparison
Compare GRPN & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRPN
- BCYC
- Stock Information
- Founded
- GRPN 2008
- BCYC 2009
- Country
- GRPN United States
- BCYC United Kingdom
- Employees
- GRPN N/A
- BCYC N/A
- Industry
- GRPN Advertising
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- GRPN Consumer Discretionary
- BCYC Health Care
- Exchange
- GRPN Nasdaq
- BCYC Nasdaq
- Market Cap
- GRPN 534.1M
- BCYC 587.5M
- IPO Year
- GRPN 2011
- BCYC 2019
- Fundamental
- Price
- GRPN $18.53
- BCYC $7.85
- Analyst Decision
- GRPN Buy
- BCYC Buy
- Analyst Count
- GRPN 4
- BCYC 8
- Target Price
- GRPN $17.75
- BCYC $29.14
- AVG Volume (30 Days)
- GRPN 2.3M
- BCYC 326.1K
- Earning Date
- GRPN 03-11-2025
- BCYC 05-01-2025
- Dividend Yield
- GRPN N/A
- BCYC N/A
- EPS Growth
- GRPN N/A
- BCYC N/A
- EPS
- GRPN N/A
- BCYC N/A
- Revenue
- GRPN $492,557,000.00
- BCYC $35,275,000.00
- Revenue This Year
- GRPN $2.91
- BCYC N/A
- Revenue Next Year
- GRPN $7.41
- BCYC $0.27
- P/E Ratio
- GRPN N/A
- BCYC N/A
- Revenue Growth
- GRPN N/A
- BCYC 30.76
- 52 Week Low
- GRPN $7.75
- BCYC $7.85
- 52 Week High
- GRPN $19.17
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- GRPN 76.50
- BCYC 26.05
- Support Level
- GRPN $9.21
- BCYC $8.60
- Resistance Level
- GRPN $19.17
- BCYC $9.69
- Average True Range (ATR)
- GRPN 0.98
- BCYC 0.68
- MACD
- GRPN 0.27
- BCYC -0.03
- Stochastic Oscillator
- GRPN 88.87
- BCYC 0.00
About GRPN Groupon Inc.
Groupon Inc acts as the middleman between consumers and merchants, offering a variety of products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.